ARQT
NASDAQArcutis Biotherapeutics Inc.
News · 26 weeks85+113%
2026-03-012026-08-23
Mix4290d
- Insider21(50%)
- Other9(21%)
- SEC Filings8(19%)
- Leadership2(5%)
- Earnings2(5%)
Latest news
25 items- INSIDERDirector Curran Terrie sold $27,912 worth of shares (1,072 units at $26.04) and exercised 1,072 shares at a strike of $7.51 (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Burnett Patrick sold $45,819 worth of shares (1,697 units at $27.00), decreasing direct ownership by 1% to 117,592 units (SEC Form 4) (tax withholding)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRPrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic DermatitisHealth Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for young children, with clinical studies demonstrating significant improvements in disease severity as early as Week 1Long-term extension study demonstrated a consistent safety profile through 56 weeksTORONTO, Aug. 20, 2026 /CNW/ -- Arcutis Canada, Inc., a commercial stage company focused on delivering meaningful innovations in immuno-dermatology, today announced that Health Canada has approved PrZORYVE® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis (AD)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $123,835 worth of shares (4,730 units at $26.18) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 36,475 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDEROfficer Burnett Patrick exercised 15,000 shares at a strike of $3.64 and sold $394,897 worth of shares (15,000 units at $26.33) (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis’ common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis’ common stock to 24 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026, as a material inducement to the new employees in connectio
- SECSEC Form SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDEROfficer Burnett Patrick sold $24,942 worth of shares (955 units at $26.12), decreasing direct ownership by 0.79% to 119,289 units (SEC Form 4) to satisfy withholding tax4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Matsuda Masaru sold $32,124 worth of shares (1,230 units at $26.12), decreasing direct ownership by 0.97% to 126,171 units (SEC Form 4) (withholding tax)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Watanabe Todd sold $114,261 worth of shares (4,375 units at $26.12), decreasing direct ownership by 0.61% to 717,203 units (SEC Form 4) to satisfy tax liability4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 10-Q filed by Arcutis Biotherapeutics Inc.10-Q - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- SECArcutis Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis Announces Second Quarter 2026 Financial Results and Provides Business UpdateContinued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growthCompany raising 2026 full-year net product sales guidance to $525 million–$540 millionReceived approval to expand the indication for ZORYVE cream 0.3% for the topical treatment of plaque psoriasis to children down to the age of 2, the seventh FDA approval in four yearsFDA accepted sNDA for ZORYVE cream 0.05% to expand indication to include infants with mild to moderate atopic dermatitis aged 3 to 24 months and set target action date of February 23, 2027Completed enrollment of the Phase 2 trial of ZOR
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDERDirector Peetz Christopher was granted 4,315 shares (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERNew insider Peetz Christopher claimed ownership of 187,500 shares (SEC Form 3)3 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $127,284 worth of shares (4,730 units at $26.91) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 37,109 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECArcutis Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)
- PRArcutis Expands Board of Directors with Appointment of Chris PeetzWESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher "Chris" Peetz has been appointed to the Arcutis Board of Directors effective July 15, 2026. "We are delighted to welcome Chris Peetz to our Board of Directors at a pivotal time for Arcutis," said Frank Watanabe, president and chief executive officer of Arcutis. "Chris has built an impressive track record leading biopharmaceutical companies through periods of expansion, from advancing multiple products through development, to building commerci
- PRArcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, August 5, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day. A live webcast of the call and related presentation materials will be available on the "Events" section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the c
- PRAttovia Therapeutics Appoints John W. Smither to Board of DirectorsSAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. ("Attovia" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee. "We are pleased to welcome John to our Board," said Tao Fu, Founder and Chief Executive Officer of Attovia. "John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public and private biotechnology companies,
- PRFDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 MonthsFDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study1 million children under the age of 2 are treated topically for atopic dermatitis in the United States, representing 10% of all adults and children treated topically for atopic dermatitis WESTLAKE VILLAGE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (
ARQT FAQ
7 questionsWhat does Arcutis Biotherapeutics Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252...Where does ARQT stock trade?
Arcutis Biotherapeutics Inc. (ARQT) is listed on NASDAQ.What sector and industry is ARQT in?
Arcutis Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcutis Biotherapeutics Inc. go public?
Arcutis Biotherapeutics Inc. (ARQT) completed its IPO in 2020.What are analysts saying about ARQT?
Arcutis Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Neutral with a $1800.00 price target on 2025-07-25.What companies are similar to ARQT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARQT side-by-side with any of them on Quantisnow.How can I track ARQT on Quantisnow?
Quantisnow aggregates Arcutis Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARQT to receive live email and push alerts on every new disclosure.